Amgen's Subcutaneous TED Drug Success Tanks Viridian Therapeutics Stock 26%
VRDN sits 44% above its 52-week low of $9.9 on elevated volume (4.4× avg).
Summary
Viridian Therapeutics' stock plummeted 26% following Amgen's announcement of positive Phase 3 results for its subcutaneous thyroid eye disease (TED) treatment, Tepezza OBI. Amgen's data showed efficacy comparable to its existing intravenous Tepezza, which is currently the only FDA-approved TED medication. This development introduces a significant competitive threat to Viridian, which recently reported positive Phase 3 data for its own subcutaneous TED treatment, Elegrobart, on March 30th. The success of Amgen's competing subcutaneous therapy directly challenges Viridian's market opportunity and competitive positioning, fundamentally altering the investment outlook despite Viridian's recent clinical advancements. Traders will now be watching for further details on Amgen's regulatory timeline and how Viridian plans to address this intensified competitive landscape.
At the time of this announcement, VRDN was trading at $14.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $9.90 to $34.29. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.